The ability of subnanomolar concentrations of thrombin to protect both neurons and glia from ischemia and other metabolic insults has recently been reported. In this study, we demonstrate an additional neuroprotective property of thrombin; its ability to promote the release of the organic osmolyte, taurine, in response to hypoosmotic stress. Incubation of human 1321N1 astrocytoma cells with hypo-osmolar buffers (320 -227 mOsM) resulted in a time-dependent release of taurine. Inclusion of thrombin (EC 50 ϭ 60 pM) resulted in a marked increase in taurine efflux that, although evident under isotonic conditions (340 mOsM), was maximal at an osmolarity of 270 mOsM (3-4-fold stimulation). Thrombin-stimulated taurine efflux was dependent upon its protease activity and could be mimicked by addition of the peptide SFLLRN, a proteinase activated receptor-1 (PAR-1) subtype-specific ligand. Inclusion of anion channel blockers known to inhibit the volume-sensitive organic osmolyte anion channel attenuated thrombin-stimulated taurine release. Depletion of intracellular Ca 2ϩ with either 1,2-bis(oaminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA) or thapsigargin, or alternatively, inhibition of protein kinase C (PKC) with bisindolylmaleimide or chelerythrine resulted in a 30 to 50% inhibition of thrombin-stimulated taurine efflux. Under conditions in which intracellular Ca 2ϩ was depleted and PKC activity inhibited, thrombin-stimulated taurine efflux was reduced by Ͼ85%. The results indicate that activation of PAR-1 receptors by thrombin facilitates the ability of 1321N1 astrocytoma cells to release osmolytes in response to a reduction in osmolarity via a mechanism that is dependent on intracellular Ca 2ϩ and PKC activity.
nel blockers known to inhibit the volume-sensitive organic osmolyte anion channel attenuated thrombin-stimulated taurine release. Depletion of intracellular Ca 2ϩ with either 1,2-bis(oaminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA) or thapsigargin, or alternatively, inhibition of protein kinase C (PKC) with bisindolylmaleimide or chelerythrine resulted in a 30 to 50% inhibition of thrombin-stimulated taurine efflux. Under conditions in which intracellular Ca 2ϩ was depleted and PKC activity inhibited, thrombin-stimulated taurine efflux was reduced by Ͼ85%. The results indicate that activation of PAR-1 receptors by thrombin facilitates the ability of 1321N1 astrocytoma cells to release osmolytes in response to a reduction in osmolarity via a mechanism that is dependent on intracellular Ca 2ϩ and PKC activity.
Recent evidence indicates that in addition to its role in platelet aggregation and tissue repair, thrombin, a serine protease generated from prothrombin, regulates numerous physiological and pathological responses including development, inflammation, atherogenesis, stroke, and Alzheimer's disease (Gingrich and Traynelis, 2000; Xi et al., 2003; Ossovskaya and Bunnett, 2004; Suo et al., 2004) . Thrombin may also be produced in the brain following cerebral hemorrhage or disruption of the blood brain barrier. It mediates its cellular functions through a family of receptors known as proteinase activated receptors (PARs). PARs belong to the superfamily of G-protein-coupled receptors that operate via G q , G i , or G 12/13 families of G-proteins, and currently, four members of the group (PAR1, PAR2, PAR3, and PAR4) have been identified. PARs have a unique activation mechanism. They are activated by an irreversible proteolytic cleavage of the receptor's extracellular N terminus, thus unmasking a new N terminus that functions as a tethered peptide ligand, which then binds intramolecularly to the receptors and initiates intracellular signal transduction (Macfarlane at al., 2001; Hollenberg and Compton, 2002; Trejo, 2003; Wang and Reiser, 2003) .
All four PARs are expressed abundantly in the central nervous system (Striggow et al., 2001) ; however, their function is still unclear. Previous studies indicate biphasic and dose-dependent actions of thrombin on astrocytes. Low concentrations of thrombin (50 pM to 100 nM) mediate neuroprotection against ischemia and environmental insults such as oxidative stress, hypoglycemia, hypoxia, and growth supplement deprivation. High concentrations of thrombin however, can cause degeneration and cell death (Vaughan et al., 1995; Striggow et al., 2000; Jiang et al., 2002) . In vivo, pretreatment of the brain with a low dose of thrombin attenuates brain injury induced by cerebral hemorrhage or trauma, although high-dose thrombin infusion can cause astrogliosis (Xi et al., 1999; Masada et al., 2000) . It has also been demonstrated that PAR1 and PAR3 receptors are upregulated in various regions of the brain after environmental insults (Xi et al., 2003) . Recently, PAR1 and PAR3 were shown to mediate antiapoptotic signaling by activated protein C in neurons (Guo et al., 2004) . Although these studies indicate the potential importance of low concentration of thrombin for the development of new therapeutic strategies to treat neurodegenerative disorders, the molecular mechanism(s) underlying neuroprotection remain to be established.
A neuroprotective mechanism used by both neurons and glia is that of volume regulation following exposure of the cells to osmotic insult. In response to hypotonic stress, cells swell with a magnitude proportional to the reduction in osmolarity. This rapid increase in volume is transient and followed by a recovery process of regulatory volume decrease (RVD), during which intracellular osmolytes (K ϩ , Cl Ϫ , and organic osmolytes) are extruded and cell volume normalized following the exit of intracellular water (McManus et al., 1995) . Of the organic osmolytes used by cells, taurine is ideally suited because of its abundance, water solubility, and metabolic inertness (Lambert, 2004) . Swelling of neural cells due to fluctuations in osmolarity is very common in elderly, infants, and during pregnancy. It can be derived from excessive water intake, such as occurs in athletes and psychotic polydipsia, or alternatively in conditions such as glucocorticoid deficiency, hypothyroidism, use of thiazide diuretics, and renal or hepatic failure (Kimelberg, 2000; Pasantes-Morales et al., 2000 . The principal cell type involved in volume regulation within the central nervous system is the astrocyte, since these cells comprise up to 90% of cell number within the brain. The importance of taurine release in RVD is indicated from studies in which taurine-deficient astrocytes were shown to exhibit a less efficient volume recovery in comparison with control cells (Moran et al., 1994a,b) . The extrusion of taurine occurs predominantly via a channel known as volume-sensitive organic osmolyte anion channel (VSOAC). VSOAC is a chloride channel, impermeable to cations (for review, see Nilius et al., 1997; Lang et al., 1998; Nilius and Droogmans, 2003) . Taurine efflux, as well as RVD, can be blocked by classic nonselective Cl Ϫ channel inhibitors, such as 1,9-dideoxyforskolin (DDF), 5-nitro-2-(3-phenypropylamine)benzoic acid (NPPB), 4,4Ј diisothiocyano-2-2Ј disulfonic stilbene (DIDS), and 4-acetamido-4 isothiocyano-2-2Ј disulfonic stilbene (SITS).
In the present study, we demonstrate that subnanomolar concentrations of thrombin, operating primarily via a PAR-1 receptor, facilitate the volume-sensitive efflux of taurine from human astrocytoma cells. Thrombin-stimulated taurine efflux is mediated via a VSOAC channel and intracellular Ca 2ϩ and protein kinase C (PKC) are implicated in the mechanism of osmolyte release. A preliminary account of part of this study has previously been reported (Cheema et al., 2005) . Cell Culture Conditions. 1321N1 astrocytoma cells (passages 5-21) were grown in tissue culture flasks (75 cm 2 /250 ml) in 20 ml of DMEM supplemented with 10% (v/v) of fetal calf serum with 1% penicillin/streptomycin. The osmolarity of the medium was 330 to 340 mOsM. Cells were grown at 37°C in a humidified atmosphere containing 10% CO 2 . The medium was aspirated and the cells detached from the flask with a trypsin-versene mixture (Cambrex Bio Science Walkersville). Cells were then resuspended in DMEM/10% fetal calf serum with penicillin/streptomycin and subcultured into 35-mm, six-well culture plates for 3 to 5 days. Experiments were routinely conducted on cells that had reached 50 to 90% confluence.
Materials and Methods
Preparation of Primary Astrocyte Cultures. Neonatal cultures of rat astrocytes were prepared from 2-day-old rats (SpragueDawley) essentially according to the method previously described (Jiang et al., 2002) .
Measurement of Taurine Efflux. Osmolyte efflux from 1321N1 astrocytoma cells was monitored essentially as previously described (Loveday et al., 2003; Heacock et al., 2004) . In brief, cells were prelabeled overnight with 18.5 KBq/ml of [ 3 H]taurine at 37°C. Under these conditions, approximately 10 to 20% of the added radiolabel was taken up into the cells. Uptake of radiolabel into 1321N1 cells was time-dependent (t 1/2 ϳ 7 h), temperature-sensitive (inhibited Ͼ98% by lowering the temperature to 4°C), and was inhibited by 75 to 80% by inclusion of a 500 M guanidinethyl sulfonate, an inhibitor of the taurine uptake transporter (Lambert, 2004) . After prelabeling, the cells were washed with 2 ϫ 2 ml of isotonic buffer A (142 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl 2 , 3.6 mM NaHCO 3 , 1 mM MgCl 2 , and 30 mM HEPES, pH 7.4, 1 mg/ml D-glucose; approximately 340 mOsM). Cells were then allowed to incubate in 2 ml of hypotonic buffer A (320 -200 mOsM; rendered hypotonic by a reduction in NaCl concentration) in the absence or presence of thrombin. In some experiments, buffer A was made hypertonic (370 mOsM) by the addition of NaCl. Osmolarities of buffer A were monitored by means of an Osmette precision osmometer (PS Precision Systems, Sudbury, MA). At times indicated, aliquots (200 l) of the extracellular medium were removed and radioactivity determined after the addition of 5 ml of Universol scintillation fluid. The reactions were terminated by rapid aspiration of the buffer and cells lysed by the addition of 2ϫ 1 ml of ice-cold 6% (w/v) trichloroacetic acid. Taurine efflux was calculated as a fractional release, i.e., the radioactivity released in the extracellular media as a percentage of the total radioactivity present initially in the cells. The latter was calculated as the sum of radioactivity recovered in the extracellular medium and that remaining in the lysate at the end of the assay (Novak et al., 1999) .
Basal release of taurine is defined as that which occurs at a specified osmolarity in the absence of thrombin.
Measurement of Phosphoinositide Turnover. To monitor phosphoinositide turnover, 1321N1 cells that had been prelabeled with 148 KBq/ml [ 3 H]inositol for 96 h were incubated in hypotonic buffer A (270 mOsM) that contained 5 mM LiCl. The accumulation of radiolabeled inositol phosphates present in the trichloroacetic acid cell lysates was determined as previously described (Thompson and Fisher, 1990) .
Measurement of Cytoplasmic Calcium Concentration. Cytoplasmic free calcium concentrations ([Ca 2ϩ ] i ) were determined in suspensions of 1321N1 astrocytoma cells after preloading cells with the Ca 2ϩ indicator, fura-2 AM (Molecular Probes, Eugene, OR), as previously described (Fisher et al., 1989) . The fluorometer used was a Shimadzu RF-5301PC spectrofluorometer (Shimadzu Scientific Instruments, Columbia, MD).
Data Analysis. Experiments were performed in triplicate and repeated at least three times. Values quoted are given as means Ϯ S.E.M. for the number of independent experiments indicated. A two-tailed Student's t test (paired) was used to evaluate differences between two experimental groups (level of significance, p Ͻ 0.05). One-way or repeated measures analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test were used for statistical significance of differences between multiple groups. EC 50 values were obtained using Prism 3.03 (GraphPad Software Inc., San Diego, CA).
Results

Osmosensitive Efflux of Taurine from 1321N1 Astrocytoma Cells Is Enhanced by the Addition of Thrombin. When 1321N1 astrocytoma cells that had been prelabeled with [
3 H]taurine were exposed to hypotonic buffer (270 mOsM), there was a time-dependent release of the radiolabeled amino acid from the cells (Fig. 1A) . The initial rate of release monitored over the first 5 min was greater than that observed following prolonged incubations. Inclusion of thrombin (0.25U/ml equivalent to 1.25 nM) significantly enhanced the rate of release of taurine at all time points examined and increased the magnitude of response by approximately 3-fold over basal (basal release being that monitored in the absence of thrombin; Fig. 1A ). If 1321N1 cells were first exposed to hypotonic buffer for 10 min and then thrombin added (i.e., after the initial rapid phase of taurine efflux), a significant stimulation of taurine release was still observed (Fig. 1B) . As a result of these observations, taurine efflux was routinely monitored after a 20-min incubation in subsequent experiments. The addition of thrombin resulted in a concentration-dependent stimulation of taurine efflux with a maximum effect observed at 1.25 nM (Fig. 2) . The EC 50 value for thrombin-stimulated taurine release from 1321N1 astrocytoma was 0.06 nM.
Thrombin Enhances Osmosensitive Taurine Release via the PAR-1 Receptor. To determine whether the ability of thrombin to enhance taurine release was mediated via its protease action at a receptor, two series of experiments were performed. In the first, thrombin was pretreated with 4 M D-Phe-Pro-Arg chloromethyl ketone (PPACK), a protease inhibitor. Although PPACK had no effect on basal taurine 3 H]taurine were washed twice with 2 ml of isotonic buffer A before incubation in 270 mOsM buffer A in the presence or absence of 1.25 nM thrombin (added at time 0, as indicated by the arrow). Reactions were terminated at the times indicated, and taurine efflux was measured. Results are expressed as taurine efflux (percentage of total soluble radioactivity) and are the means Ϯ S.E.M. for triplicate replicates. Data shown represent three experiments. B, cells were treated as described in A with the exception that cells were allowed to incubate for 10 min in hypotonic buffer A (270 mOsM) prior to the addition of thrombin (indicated by arrow).
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org release, it essentially abolished the ability of thrombin to enhance taurine release (Fig. 3A) . In a second series of experiments, the ability of three synthetic PAR peptides to enhance taurine release was evaluated. Addition of 100 M SFFLRN, a synthetic peptide specific for PAR-1 subtype, significantly increased taurine release over basal (275% of basal; Fig. 3B ). This enhancement, which was also observed with 100 M TFFLRN, an additional PAR-1-specific peptide, was similar in magnitude to that observed for thrombin. Although inclusion of 500 M PAR-3-specific peptide (TFR-GAP) also increased taurine release, the effect was not significant and was markedly less than that of the PAR-1 agonist. In contrast, the addition of the PAR-4 peptide, GYPGKF, did not significantly increase taurine release over basal. Taken collectively, these data indicate that the ability of thrombin to enhance taurine release in 1321N1 astrocytoma is mediated primarily by the PAR-1 receptor subtype. The ability of thrombin to stimulate taurine release under hypotonic conditions was also observed for primary cultures of rat astrocytes, although the effect was less marked (148% of basal; Fig. 3C ) than that observed for 1321N1 astrocytoma cells.
Thrombin Enhances the Volume-Sensitive Efflux of Taurine from 1321N1 Astrocytoma Cells as Osmolarity Decreases. The ability of thrombin to potentiate the release of taurine at different osmolarities was examined. Both basal-and thrombin-stimulated release of taurine was monitored under conditions of isotonicity (340 mOsM; defined by the osmolarity of the DMEM/fetal calf serum medium in which the cells are grown), mild to severe hypotonicity (320 -227 mOsM), or mild hypertonicity (370 mOsM). In the series of experiments conducted, the basal release of taurine was not significantly enhanced until the osmolarity of the buffer had been reduced to 227 mOsM. In contrast, the addition of thrombin resulted in a significant increase in taurine efflux (279% of basal) even under isotonic conditions (Fig. 4) . Moreover, as the osmolarity of the buffer was reduced, the ability of thrombin to enhance taurine efflux over the basal component was further increased. The maximum enhancement of taurine efflux was observed at an osmolarity of 270 mOsM (442% of basal). In contrast, when cells were exposed to mildly hypertonic buffer A (370 mOsM), the addition of thrombin did not significantly enhance taurine release. As a result of these findings, an osmolarity of 270 mOsM was chosen for all subsequent experiments.
Taurine Efflux from 1321N1 Astrocytoma Is Mediated via a VSOAC. To determine whether thrombin-stimulated taurine release occurred via a VSOAC, the ability of four anion channel inhibitors, all of which are putative blockers of the VSOAC channel, to inhibit the basal and thrombinstimulated efflux of taurine was examined. All four anion channel inhibitors resulted in a significant inhibition of both basal-and thrombin-stimulated taurine release (Fig. 5) . At a concentration of 100 M, dideoxyforskolin and NPPB were more effective at inhibiting taurine release than either of the stilbene derivatives, DIDS and SITS (67-94% inhibition ver- Since the PAR-1 subtype is known to couple to the pertussis toxin-sensitive G i subfamily of heterotrimeric G-proteins (Coughlin, 2000) , we tested the ability of pertussis toxin to inhibit thrombin-stimulated taurine release. Overnight pretreatment of the cells with pertussis toxin (60 ng/ml) resulted in a small reduction in basal release of taurine (68 Ϯ 9% of control, n ϭ 6), whereas thrombin-stimulated taurine efflux was unaffected (387 Ϯ 54% versus 509 Ϯ 29% of basal for untreated and pertussis toxin-treated cells, respectively, n ϭ 6).
To examine the possibility that other known mediators of PAR-1 activation were involved in the thrombin-induced taurine release, cells were incubated with wortmannin (100 nM), a phosphatidylinositol 3-kinase inhibitor or PD 98059 (50 M), mitogen activated protein kinase inhibitor (Wang et al., 2002) , and KN-93 (10 M), a Ca 2ϩ CaMK II inhibitor. No significant effect on either basal or thrombin-stimulated taurine release was observed for any of these inhibitors (data not shown).
Taurine Release from 1321N1 Astrocytoma Cells Is Enhanced following a Rise in the Concentration of Intracellular Calcium or Activation of Protein Kinase C. Activation of thrombin receptors on 1321N1 astrocytoma cell has also been reported to elicit an increase in the activity of phospholipase C (PLC) mediated via G q , with a concomitant rise in the concentration of cytoplasmic calcium ([Ca 2ϩ ] i ) and activation of PKC (Jones et al., 1989) . In agreement with these previous observations, the addition of thrombin to 1321N1 cells (incubated in hypotonic buffer A) resulted in a small, but significant, increase in the release of inositol phosphates (146 and 174% of basal after 5 or 10 min, respectively; Fig. 6A ). Thrombin addition also elicited a rise in [Ca 2ϩ ] i (592 Ϯ 78 versus 196 Ϯ 23 nM for basal, n ϭ 13), which was markedly attenuated when extracellular Ca 2ϩ was omitted (69 Ϯ 4% inhibition, n ϭ 14; Fig. 6B ). In the absence of extracellular Ca 2ϩ , the depletion of intracellular Ca 2ϩ stores with 5 M thapsigargin further reduced the ability of thrombin to increase [Ca 2ϩ ] i (89 Ϯ 2% inhibition, n ϭ 8). A rise in [Ca 2ϩ ] i , mediated by the addition of 1 M ionomycin (which facilitates both the influx of extracellular Ca 2ϩ and the release of Ca 2ϩ from intracellular stores), partially mimicked the ability of thrombin to enhance taurine efflux from the astrocytoma cells (165% of basal; Fig. 7A) . A similar significant increase in taurine release was observed following the addition of PMA, a PKC agonist (170% of basal; Fig. 7A ), whereas its inactive analog, 4-␣-phorbol 12,13-didecanoate, was without effect (data not shown). When both PMA and ionomycin were added to the hypotonically treated cells, their effect on taurine release was additive (219% of basal). However, thrombin-stimulated taurine efflux was not further enhanced by the presence of either PMA or ionomycin (Fig. 7B) .
To determine the role, if any, played by Ca 2ϩ in basal-and thrombin-stimulated taurine efflux, taurine release was monitored under conditions in which extracellular and/or intracellular Ca 2ϩ had been depleted. Removal of extracellular Ca 2ϩ had little or no effect on either basal-or thrombinstimulated taurine efflux (Fig. 8A) . In contrast, chelation of intracellular Ca 2ϩ with BAPTA-AM significantly reduced the extent of the thrombin-stimulated taurine efflux (56% inhibition), whereas basal efflux was unaffected. To further examine the role of intracellular Ca 2ϩ in osmolyte release, the cells were preincubated with 5 M thapsigargin (in the ab- sence of extracellular Ca 2ϩ ) to discharge the intracellular Ca 2ϩ pools. Under these conditions, the ability of thrombin to stimulate taurine efflux was reduced by 52% (Fig. 8B) .
To test the involvement of PKC in thrombin-stimulated taurine efflux, cells were preincubated with either 1 M BIM or 10 M chelerythrine. Although BIM slightly decreased the basal taurine efflux, both BIM and chelerytherine significantly attenuated thrombin-stimulated taurine release (30% inhibition; Fig. 9A ). Down-regulation of PKC following overnight incubation of the cells with 100 nM PMA also resulted in reduction in an inhibition of thrombin-stimulated taurine efflux (54 Ϯ 6% versus control cells, n ϭ 3). The combination of inhibition of PKC with 10 M chelerythrine, along with depletion of intracellular Ca 2ϩ with 5 M thapsigargin, resulted in an 87% inhibition of thrombin-stimulated taurine release (Fig. 9B) .
Discussion
Subnanomolar concentrations of thrombin have been demonstrated to protect both neurons and astrocytes against metabolic insults such as hypoglycemia, ischemia, or oxidative stress (Vaughan et al., 1995; Striggow et al., 2000) . In the present study, we demonstrate that similarly low concentrations of thrombin also markedly increase the release of taurine, an organic osmolyte, from human 1321N1 astrocy- 3 H]taurine were washed with isotonic buffer A and then incubated in hypotonic buffer A (270 mOsM) with or without PMA (100 nM), ionomycin (1 M), or both. Reactions were terminated after 20 min, and taurine efflux was monitored. Results are expressed as taurine efflux (percentage of total soluble radioactivity) and are the means Ϯ S.E.M. for six independent experiments, each performed in triplicate. ‫,ءء‬ different from control, p Ͻ 0.01 (by repeated measures ANOVA followed by Dunnett's multiple comparisons test). B, cells were treated as described in A but incubated with thrombin (1.25 nM) in the absence or presence of PMA or ionomycin. Results are expressed as taurine efflux (percentage of total soluble radioactivity) and are the means Ϯ S.E.M. for four independent experiments. Thrombin-stimulated taurine efflux was not increased by the presence of either PMA or ionomycin. toma cells following a mild hypoosmotic insult. The ability of thrombin to enhance taurine release, which is dependent on its protease activity, occurs rapidly (within 1-2 min of addition) and can be observed regardless of whether thrombin is added prior to or after the initiation of taurine release (Fig. 1,  A and B) . The concentrations of thrombin required to enhance taurine release (EC 50 ϭ 60 pM) are similar to those previously demonstrated to provide neuroprotection (Fig. 2) . Based upon the ability of the receptor-specific peptides SFLLRN and TFLLRN to fully mimic the ability of thrombin to enhance taurine release (and the relative ineffectiveness of PAR-3-and PAR-4-specific peptides), it seems that the PAR-1 receptor subtype is primarily responsible for thrombin-stimulated osmolyte release (Fig. 3B) . Although an astrocytoma cell line was primarily used for the present study, we observed that the addition of thrombin to primary cultures of rat brain astrocytes incubated under hypoosmotic conditions also resulted in a stimulation of taurine release above basal (Fig. 3C) . Although the ability of thrombin to stimulate osmolyte release has previously been reported for myoblasts , to the best of our knowledge, the present results are the first to indicate a similar role for thrombin in neural tissues and to identify the receptor subtype involved. Thus, one of the in vivo functions of thrombin in the brain, whether synthesized within the CNS or resulting from cerebral hemorrhage or a compromised blood-brain barrier, may be that of osmoregulation.
The pharmacological profile of inhibition of both basal-and thrombin-stimulated taurine efflux from 1321N1 astrocytoma cells by anion channel inhibitors is consistent with the involvement of a VSOAC in osmolyte release. Thus, taurine efflux was significantly inhibited by DIDS, SITS, NPPB, and DDF, all of which are purported to be inhibitors of volumesensitive anion channels . However, as previously observed for the volume-dependent efflux of taurine from SH-SY5Y neuroblastoma cells (Heacock et al., 2004) , DDF and NPPB are markedly more potent inhibitors of osmolyte release from the astrocytoma cells than either of the two stilbene derivatives, DIDS and SITS.
One notable feature of thrombin-stimulated taurine efflux is that the protease is able to substantially enhance osmolyte release (279% of basal) even under isotonic conditions (340 mOsM; Fig. 4 ). This result suggests that even though the VSOAC primarily responds to a reduction of osmolarity, the channel is partially open under conditions of isotonicity but not under hypertonic conditions (370 mOsM). The ability of receptor activation to enhance osmolyte release under isotonic conditions has been observed previously. For example, ATPinduced D-aspartate release from astrocytes and muscarinic cholinergic receptor (mAChR)-mediated taurine efflux from neuroblastoma cells can be observed under isotonic conditions (Mongin and Kimelberg, 2002; Heacock et al., 2004 ). In contrast, the mAChR-stimulated release of myo-inositol, another quantitatively major organic osmolyte, was not observed under isotonic conditions (Loveday et al., 2003) . In this context, it should be noted that the ability of organic osmolytes to permeate VSOAC is dependent upon their molecular dimensions. Since the minimum diameter of the pore channel of the VSOAC is reported to be between 5. 4 and 8.0 Å (McManus et al., 1995; Nilius et al., 1997) , osmolytes such as glutamate, D-aspartate, or taurine will readily exit the cells, whereas myo-inositol, whose molecular dimensions are close to the pore diameter, is 
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org released less readily. Although activation of PAR-1 receptors on astrocytoma cells can enhance taurine release under isotonic conditions, its effects become even more pronounced when the osmolarity is reduced by 5 to 20%, conditions under which the basal release of taurine is only minimally increased (Fig. 4) . These results are consistent with the concept that PAR-1 activation facilitates the ability of the cells to release osmolytes (and, by inference, to regulate their volume) under conditions of very limited reductions in osmolarity, i.e., those that might be expected to pertain to physiological or pathological conditions in vivo.
Although PAR-1 receptors are pleiotropic and can couple to multiple GTP-binding proteins, thereby activating a diverse array of signaling pathways (Coughlin, 2000; Trejo, 2003) , our data suggest that Ca 2ϩ and PKC play the major roles in facilitation of taurine release. The evidence for this is as follows. First, the ability of thrombin to enhance taurine release could be mimicked, in part at least, by the addition of the Ca 2ϩ ionophore, ionomycin. Second, the mobilization of an intracellular pool of Ca 2ϩ seems to be required since either chelation of intracellular Ca 2ϩ with BAPTA or discharge of the pool with thapsigargin resulted in a 52 to 56% inhibition of thrombin-stimulated taurine efflux. In contrast, removal of extracellular Ca 2ϩ had no effect on the magnitude of efflux. The reliance of thrombin-stimulated taurine release on intracellular (rather than extracellular) stores of Ca 2ϩ contrasts with the Ca 2ϩ signals generated in fura-2 loaded cells upon thrombin addition, which depend on both sources of Ca 2ϩ (Fig. 6B ). This result suggests that thrombin-stimulated taurine release may require a rise in [Ca 2ϩ ] i , and the magnitude of osmolyte release is not directly proportional to that of the Ca 2ϩ signal. Moreover, it seems that a significant fraction of thrombin-stimulated osmolyte release can still occur in the absence of Ca 2ϩ (see Fig. 8B ). Although thrombin addition results in an activation of PLC (Fig. 6A ) and a rise in [Ca 2ϩ ] i in these cells, an obligatory link between this pathway and osmolyte release is yet to be established because of the absence of a specific inhibitor of PLC (see Loveday et al., 2003) .
A role for PKC is indicated from the ability of PMA, when added alone, to stimulate taurine efflux and from the observation that either BIM or chelerythrine, two inhibitors of PKC, can inhibit thrombin-stimulated taurine release. Further indication of the involvement of PKC was obtained from experiments in which down-regulation of the enzyme, following an overnight incubation of the cells with PMA, resulted in an attenuation of thrombin-stimulated taurine efflux. Under conditions in which both intracellular Ca 2ϩ is depleted and PKC inhibited, thrombin's ability to stimulate osmolyte release was inhibited by 87%. In contrast to the Ca 2ϩ and PKC dependence of thrombin-stimulated taurine efflux, the basal release of taurine is not dependent on either parameter. This suggests that the ability of thrombin to activate VSOAC involves signaling pathways that are distinct from those elicited by hypotonicity alone. A requirement for Ca 2ϩ and PKC in receptor-regulated osmolyte release is emerging as a general characteristic (Loveday et al., 2003; Mongin and Kimelberg, 2005) . However, the source of Ca 2ϩ may differ depending upon the receptor and/or cell type (Loveday et al., 2003) . Both PKC and Ca 2ϩ calmodulindependent protein kinase II are potential downstream targets for Ca 2ϩ activation. However, the inability of KN-93 to inhibit thrombin-stimulated taurine efflux suggests that Ca 2ϩ calmod- at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
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ulin-dependent protein kinase II is not involved in VSOAC regulation. Although the general characteristics of swelling-induced osmolyte release from neural cells have been extensively examined, only recently has evidence emerged that certain pharmacologically distinct receptors such as the P2Y purinergic, M 3 -mAChR and now PAR-1, are able to positively regulate osmolyte efflux. There are two major implications of these findings. The first is that the ability of receptors to stimulate osmolyte release suggests that the process in vivo whereby hypoosmotically stressed cells restore their volume may be more dynamic than previously considered since these cells are also likely to be continuously subjected to neurohumoral regulation. The second is that the ability of these receptors to facilitate osmolyte release under isotonic conditions via VSOAC raises the possibility that receptor-mediated release of another quantitatively major osmolyte in the brain, namely glutamate, which also functions as a neurotransmitter, may constitute a means for intercellular signaling between glia and neurons. Although this possibility has previously been raised for ATP modulation of glutamate release from astrocytes under isotonic conditions (Jeremic et al., 2001 ), the present data raise the possibility that additional receptors may also share this property. In addition, it should be noted that taurine itself has agonist properties at both GABA A and glycine receptors (Hussy et al., 1997; Hilgier et al., 2005) .
In summary, the present data emphasize the importance of receptor regulation of osmolyte release through a VSOAC. Control of neural cell swelling is of particular importance to the CNS due to the spatial restrictions of the skull. In this case, thrombin via its PAR-1 receptor plays a role in protection of neural cells from osmotic insults and regulates volume via a mechanism dependent upon intracellular Ca 2ϩ and PKC. This role for thrombin in osmoregulation within the brain adds to the growing list of functions attributed to this protease in CNS physiology and pathology.
